Complementation of a primer binding site-impaired murine leukemia virus-derived retroviral vector by a genetically engineered tRNA-like primer.

Agriculture & Biology

• retroviral vectors 100%
• Murine leukemia virus 91%
• binding sites 55%
• synthetic genes 17%
• reverse transcription 15%
• gene transfer 13%
• nucleotides 9%
• RNA 8%
• genome 7%
• synthesis 7%

Medicine & Life Sciences

• Murine Leukemia Viruses 86%
• Transfer RNA 71%
• Binding Sites 50%
• Technology Transfer 19%
• Synthetic Genes 18%
• Reverse Transcription 11%
• Nucleotides 10%
• RNA 9%
• Genome 8%
• Genes 5%